Tags

Type your tag names separated by a space and hit enter

High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Haematologica. 2003 Dec; 88(12):1372-7.H

Abstract

BACKGROUND AND OBJECTIVES

Patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis. However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival when treated with high dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL).

DESIGN AND METHODS

We retrospectively evaluated the efficacy of ASCT in 35 patients with PTCL from the GEL-TAMO registry, who did not achieve a CR to standard induction chemotherapy regimens for aggressive NHL. Thirty-one patients underwent transplantation after achieving a partial response (PR) and 4 patients were non-responders.

RESULTS

Following HDC/ASCT, 23 (66%) of the patients achieved a CR, 4 (11%) a PR and in 7 (20%) cases the transplant failed. One patient was not evaluated because of early toxic death. With a median follow-up of the survivors of 37.5 months, 18 patients (51%) are alive and 15 patients (43%) are free of disease. Transplant-related mortality rate at 100 days was 11% and at 5 years the probabilities of survival, freedom from progression and disease-free survival for complete responders were 37%, 36% and 55% respectively. Pre-transplant lactate-dehydrogenase level, age-adjusted International Prognostic Index (aa-IPI) and tumor score correlated with survival.

INTERPRETATION AND CONCLUSIONS

One third of the patients with PTCL who fail to achieve CR to the first chemotherapeutic regimen can be rescued with HDC/ASCT. Pre-transplant values of IPI and tumor score risk systems for aggressive lymphomas were useful to predict subsequent survival.

Authors+Show Affiliations

Servicio de Hematología, Hospital Universitario Son Dureta, Av/Andrea Doria 55, Palma de Mallorca 07014, Spain. jrodriguez@hsd.esNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

14687990

Citation

Rodriguez, José, et al. "High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Peripheral T-cell Lymphoma Not Achieving Complete Response After Induction Chemotherapy. the GEL-TAMO Experience." Haematologica, vol. 88, no. 12, 2003, pp. 1372-7.
Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica. 2003;88(12):1372-7.
Rodriguez, J., Caballero, M. D., Gutierrez, A., Gandarillas, M., Sierra, J., Lopez-Guillermo, A., Sureda, A., Zuazu, J., Marin, J., Arranz, R., Carreras, E., Leon, A., De Sevilla, A. F., San Miguel, J. F., & Conde, E. (2003). High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica, 88(12), 1372-7.
Rodriguez J, et al. High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Peripheral T-cell Lymphoma Not Achieving Complete Response After Induction Chemotherapy. the GEL-TAMO Experience. Haematologica. 2003;88(12):1372-7. PubMed PMID: 14687990.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. AU - Rodriguez,José, AU - Caballero,Maria Dolores, AU - Gutierrez,Antonio, AU - Gandarillas,Marco, AU - Sierra,Jorge, AU - Lopez-Guillermo,Armando, AU - Sureda,Anna, AU - Zuazu,Javier, AU - Marin,Jesus, AU - Arranz,Reyes, AU - Carreras,Enric, AU - Leon,Angel, AU - De Sevilla,Alberto Fernández, AU - San Miguel,Jesus F, AU - Conde,Eulogio, AU - ,, PY - 2003/12/23/pubmed PY - 2006/4/7/medline PY - 2003/12/23/entrez SP - 1372 EP - 7 JF - Haematologica JO - Haematologica VL - 88 IS - 12 N2 - BACKGROUND AND OBJECTIVES: Patients with aggressive non-Hodgkin's lymphomas (NHL) who do not obtain a complete response (CR) after induction chemotherapy have a poor prognosis. However, provided they are sensitive to the first regimen of chemotherapy, 25-40% of them with a B-cell phenotype may achieve long-term survival when treated with high dose chemotherapy and autologous stem cell transplantation (HDC/ASCT). The aim of this study was to analyze the efficacy of this therapy in the corresponding patients with peripheral T-cell lymphoma (PTCL). DESIGN AND METHODS: We retrospectively evaluated the efficacy of ASCT in 35 patients with PTCL from the GEL-TAMO registry, who did not achieve a CR to standard induction chemotherapy regimens for aggressive NHL. Thirty-one patients underwent transplantation after achieving a partial response (PR) and 4 patients were non-responders. RESULTS: Following HDC/ASCT, 23 (66%) of the patients achieved a CR, 4 (11%) a PR and in 7 (20%) cases the transplant failed. One patient was not evaluated because of early toxic death. With a median follow-up of the survivors of 37.5 months, 18 patients (51%) are alive and 15 patients (43%) are free of disease. Transplant-related mortality rate at 100 days was 11% and at 5 years the probabilities of survival, freedom from progression and disease-free survival for complete responders were 37%, 36% and 55% respectively. Pre-transplant lactate-dehydrogenase level, age-adjusted International Prognostic Index (aa-IPI) and tumor score correlated with survival. INTERPRETATION AND CONCLUSIONS: One third of the patients with PTCL who fail to achieve CR to the first chemotherapeutic regimen can be rescued with HDC/ASCT. Pre-transplant values of IPI and tumor score risk systems for aggressive lymphomas were useful to predict subsequent survival. SN - 1592-8721 UR - https://www.unboundmedicine.com/medline/citation/14687990/High_dose_chemotherapy_and_autologous_stem_cell_transplantation_in_patients_with_peripheral_T_cell_lymphoma_not_achieving_complete_response_after_induction_chemotherapy__The_GEL_TAMO_experience_ L2 - http://www.diseaseinfosearch.org/result/5676 DB - PRIME DP - Unbound Medicine ER -